Omnicell (NASDAQ:OMCL) Rating Increased to Buy at StockNews.com

Omnicell (NASDAQ:OMCL) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other research firms have also recently commented on OMCL. Bank of America lifted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Finally, Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Omnicell Stock Performance

Omnicell stock opened at $41.10 on Friday. The company’s 50-day moving average price is $43.22 and its 200-day moving average price is $34.24. Omnicell has a twelve month low of $25.12 and a twelve month high of $45.84. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a market cap of $1.89 billion, a PE ratio of -89.35, a price-to-earnings-growth ratio of 47.11 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same period in the previous year, the company earned $0.29 EPS. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Trading of Omnicell

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after buying an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after buying an additional 228,093 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Omnicell during the first quarter worth $684,000. Finally, Illinois Municipal Retirement Fund purchased a new stake in Omnicell during the first quarter worth $718,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.